Tandem Diabetes Care (TNDM) Depreciation & Amortization (CF) (2013 - 2026)

Tandem Diabetes Care (TNDM) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 4.48% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $17.9 million (up 5.83% YoY), and the FY2025 full-year result was $17.7 million, up 6.38% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $4.5 million, roughly flat from $4.5 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $4.5 million in Q1 2026 and bottomed at $3.4 million in Q1 2023.
• The 5-year median for Depreciation & Amortization (CF) is $4.1 million (2024), against an average of $4.0 million.
• Peak annual rise in Depreciation & Amortization (CF) reached 20.04% in 2023, while the deepest fall reached 6.39% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.6 million in 2022, then grew by 10.71% to $4.0 million in 2023, then increased by 5.31% to $4.2 million in 2024, then gained by 5.89% to $4.5 million in 2025, then rose by 0.2% to $4.5 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $4.5 million (Q1 2026), $4.5 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.

Peer Comparison